Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.29 BRL | +0.08% |
|
+2.85% | -25.11% |
May. 08 | Transcript : Blau Farmacêutica S.A., Q1 2024 Earnings Call, May 08, 2024 | |
May. 07 | Blau Farmacêutica S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 48% by 2026.
- The company returns high margins, thereby supporting business profitability.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.93 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.11% | 403M | - | ||
+61.53% | 848B | C+ | ||
+33.98% | 627B | B | ||
-3.66% | 363B | C+ | ||
+15.06% | 318B | B- | ||
+9.18% | 299B | C+ | ||
+11.57% | 234B | A+ | ||
+15.42% | 225B | B- | ||
+15.67% | 179B | C+ | ||
+2.47% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BLAU3 Stock
- Ratings Blau Farmacêutica S.A.